Eesti - eesti - Ravimiamet

aesica queenborough limited - mitomütsiin - süstelahuse pulber - 2mg 10tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals gmbh - propranolool - tablett - 40mg 100tk; 40mg 50tk; 40mg 30tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals gmbh - lakosamiid - õhukese polümeerikattega tablett - 50mg 14tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals gmbh - lakosamiid - õhukese polümeerikattega tablett - 100mg 56tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals gmbh - alprostadiil - süstelahuse pulber ja lahusti - 40mcg 6tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals s.r.l. - levetiratsetaam - infusioonilahuse kontsentraat - 100mg 1ml 5ml 10tk

Eesti - eesti - Ravimiamet

aesica pharmaceuticals gmbh - isosorbiitdinitraat - keelealune tablett - 5mg 100tk

Eesti - eesti - Ravimiamet

bristol-myers squibb gyogyszerkereskedelmi kft. - didanosiin - gastroresistentne kõvakapsel - 400mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - parekoksiibnaatrium - valu, postoperatiivne - coxibs, antiinflammatory and antirheumatic products - operatsioonijärgse valu lühiajaliseks raviks.